Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 3/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 3/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 3/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 3/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899479 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652289 | 0.84 | GABRA1 (0.72) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL6122459 | 0.84 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653989 | 0.82 | GABRA1 (0.69) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL29618008 | 0.82 | GABRA1 (0.69) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL6121572 | 0.82 | GABRA1 (0.69) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8565250 | 0.81 | GABRA5 (0.68) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8534202 | 0.80 | GABRA1 (0.66) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8586468 | 0.80 | GABRA1 (0.66) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8534623 | 0.79 | GABRA1 (0.65) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | claimed |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | HOFFMANN LA ROCHE (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024039886-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024023268-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| CN-112409363-B | Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment | 艾吉因生物股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237530-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068161-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068149-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068161-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | GABRG2 20/4885GABRB3 8/4885GABRA5 1/4885 |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | PMP22, PARK7, NCS1 | GABRG2 425/4885GABRB3 331/4885GABRA5 101/4885 |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | GABRG2 52/4885GABRB3 62/4885GABRA5 4/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885 |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRE | GABRG2 20/4885GABRB3 11/4885GABRA5 1/4885 |
| US-20130237530-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GABRA3, GABRB3 | GABRG2 12/4885GABRB3 3/4885GABRA5 1/4885 |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885 |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRB1 | GABRG2 20/4885GABRB3 7/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.